A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide

Sponsor:

Janssen Research and Development, LLC

Sponsor Study ID:

MonumenTAL-6-64407564MMY3009

CTO #:

103914

NCT Number:

NCT06208150

Phase:

III

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Multiple Myeloma

Study Objectives:

To compare the efficacy of either Tal-P or Tal-Tec with EPd or PVd.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)